Success Metrics

Clinical Success Rate
20.0%

Based on 1 completed trials

Completion Rate
20%(1/5)
Active Trials
0(0%)
Results Posted
500%(5 trials)
Terminated
4(80%)

Phase Distribution

Ph phase_3
5
100%

Phase Distribution

0

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
5(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(4)

Detailed Status

Terminated4
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
20.0%
Most Advanced
Phase 3

Trials by Phase

Phase 35 (100.0%)

Trials by Status

completed120%
terminated480%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

NCT02024646
terminatedphase_3

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

NCT01708603
terminatedphase_3

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708629
terminatedphase_3

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

NCT01708590
terminatedphase_3

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

NCT02029495

Clinical Trials (5)

Showing 5 of 5 trials
NCT02024646Phase 3

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

Completed
NCT01708603Phase 3

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Terminated
NCT01708629Phase 3

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Terminated
NCT01708590Phase 3

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects

Terminated
NCT02029495Phase 3

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5